John A Whritner Net Worth

The estimated Net Worth of John A Whritner is at least $4.05 millier dollars as of 1 December 2008. John Whritner owns over 400 units of Artelo Biosciences Inc stock worth over $4,046 and over the last 19 years John sold ARTL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Whritner ARTL stock SEC Form 4 insiders trading

John has made over 3 trades of the Artelo Biosciences Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently John bought 400 units of ARTL stock worth $1,592 on 1 December 2008.

The largest trade John's ever made was exercising 2,500 units of Artelo Biosciences Inc stock on 8 January 2007 worth over $17,225. On average, John trades about 486 units every 99 days since 2005. As of 1 December 2008 John still owns at least 3,400 units of Artelo Biosciences Inc stock.

You can see the complete history of John Whritner stock trades at the bottom of the page.

What's John Whritner's mailing address?

John's mailing address filed with the SEC is 4 Blueberry Lane, Niantic, CT 06357, USA.

Insiders trading at Artelo Biosciences Inc

Over the last 21 years, insiders at Artelo Biosciences Inc have traded over $1,017,062 worth of Artelo Biosciences Inc stock and bought 94,621 units worth $215,565 . The most active insiders traders include Connie Matsui, Steven B Lapin et Georgia Erbez. On average, Artelo Biosciences Inc executives and independent directors trade stock every 89 days with the average trade being worth of $13,026. The most recent stock trade was executed by Gregory D. Gorgas on 12 August 2022, trading 1,200 units of ARTL stock currently worth $4,800.

What does Artelo Biosciences Inc do?

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.

Complete history of John Whritner stock trades at Artelo Biosciences Inc

Artelo Biosciences Inc executives and stock owners

Artelo Biosciences Inc executives and other stock owners filed with the SEC include:

• Gregory D. Gorgas,
  Pres, CEO, CFO, Treasurer, Sec. & Director
• Jason H. Baybutt,
  Sr. VP of Fin.
• Dr. Steven D. Reich,
  Chief Medical Officer
• Peter Michael O'Brien,
  Sr. VP of European Operations
• Dr. Andrew Yates Ph.D.,
  Sr. VP, Chief Scientific Officer & Member of Scientific Advisor Board
• Randy Schreckhise,
  VP of Fin. & Operations
• Donald T Netter,
  Director
• Brian Schlier,
  Vice President
• James G Tatum,
  Director
• John A Whritner,
  Director
• John L Lahey,
  Director
• Ira R Harkavy,
  Director
• Inc. Lrta,,
  10% owner
• Corp /De/Nasco Holdings, In...,
  
• Steven B Lapin,
  President & COO
• H William Smith,
  V.P., Gen. Counsel & Secretary
• W Phillip Niemeyer,
  Vice President-Prod. Coord.
• Dean T Johnson,
  Chief Financial Officer
• Corp /De/ Geneve,
  10% owner
• John Joseph Crawford,
  Director
• Sharon M Oster,
  Director
• Douglas Blayney,
  Director
• Connie Matsui,
  Director
• Peter Michael O'brien,
  
• Steven Kelly,
  Director
• John W Beck,
  
• Georgia Erbez,
  
• Robert Martin Emanuele,
  Director
• Gregory Reyes,
  Director
• Tamara A Favorito,
  Director
• Gregory D. Gorgas,
  Pres, CEO, CFO, Treas & Sec